DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
Registered number: 06057181 Charity number: 1124716
MELANOMA FOCUS
(A Company Limited by Guarantee)
UNAUDITED
TRUSTEES' REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2021
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
CONTENTS
| Page | |
|---|---|
| Reference and Administrative Details of the Company, its Trustees and Advisers | 1 |
| Trustees' Report | 2 - 7 |
| Independent Examiner's Report | 8 - 9 |
| Statement of Financial Activities | 10 |
| Balance Sheet | 11 - 12 |
| Notes to the Financial Statements | 13 - 27 |
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 JANUARY 2021
| Trustees | Mrs Imogen Cheese |
|---|---|
| Dr Phillippa Gail Corrie | |
| Dr Mark Harries | |
| Professor Catherine Anne Harwood | |
| Mrs Jacqueline Anne Hodgetts | |
| Professor Paul Lorigan | |
| Dr Paul Nathan | |
| Mr Alan Howard Skyrme Peach | |
| Dr Samra Turajlic | |
| Company registered number 06057181 Charity registered number 1124716 Registered office Salisbury House Station Road Cambridge CB1 2LA Chief executive officer Mr Simon Rodwell (to 14 September 2020) Ms Susanna Daniels (from 15 September 2020) Independent Examiner M Hewett ACA DChA Peters Elworthy & Moore Chartered Accountants Salisbury House Station Road Cambridge CB1 2LA Bankers NatWest 11 Western Boulevard Bede Island Leicester LE2 7EJ HSBC UK 53 High Street Newmarket Suffolk CB8 8NF Solicitors Ashtons Legal Waterfront House Wherry Quay Ipswich Suffolk IP4 1AS |
Page 1
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
TRUSTEES' REPORT FOR THE YEAR ENDED 31 JANUARY 2021
The Trustees present their annual report together with the financial statements of the Company for the year 1 February 2020 to 31 January 2021. The annual report serves the purposes of both a Trustees' report and a directors' report under company law. The Trustees confirm that the annual report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (second edition of the Charities SORP (FRS102) October 2019, effective 1 January 2019).
Since the Company qualifies as small under section 382 of the Companies Act 2006, the Strategic Report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.
OBJECTIVES AND ACTIVITIES
a. POLICIES AND OBJECTIVES
In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.
The objects of Melanoma Focus as set out in its Memorandum of Association are to:
-
Raise money to fund research into the causes and the treatment of melanoma for the public benefit;
-
Maintain authoritative information resources about the disease, its treatment and the minimisation of risk;
-
Provide practical support for patients and their families;
-
Raise awareness and promote education about melanoma and its prevention amongst the general public; 5. Advance melanoma knowledge and education among clinicians, nurses, scientists and other healthcare workers;
-
Develop clinical guidelines and consensus positions about the treatment of all forms of melanoma;
-
Act as a professional membership organisation for UK melanoma professionals, helping specialists from all disciplines to share information; and
-
Contribute to national debates on melanoma issues on behalf of patients and clinicians
The main activities undertaken to achieve these objects are support and funding for a number of research studies in the UK, together with work on national clinical guidelines and organising two scientific multidisciplinary professional meetings a year. These projects are referred to below in the Review of Activities.
In addition Melanoma Focus is engaged in a wide variety of smaller projects, including several that have a direct bearing upon patients and their carers, such as the Melanoma Helpline. Again, these are described more fully below.
Melanoma is the fifth most common cancer in the UK, with around 16,000 new melanoma cases in the UK every year, or 44 every day. It is the deadliest form of skin cancer but the outlook for people with advanced melanoma is improving, as the statistics show. Ten years ago there was little that could be done to improve the survival of those with advanced disease; now there is a range of options, including new immunotherapy drugs, which are starting to have a transformative effect. Yet it is surprising to reflect that each year more people die from skin cancer in the UK than in Australia.
Page 2
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2021
OBJECTIVES AND ACTIVITIES (CONTINUED)
b. POLICIES AND OBJECTIVES (CONT.)
We aim to improve the knowledge and understanding of all aspects of melanoma. The charity’s objectives in achieving this aim include: creating reliable and authoritative information resources and a better understanding of the disease, its treatment and avoidance available to patients, their families and the general public; improving knowledge among clinicians, scientists and others in the healthcare sector; acting as a professional membership organisation for everyone working in the melanoma field in the UK; contributing to national debates on issues affecting patients; and raising money to fund projects directly benefiting patients as well as clinical studies into aspects of the treatment of melanoma.
ACHIEVEMENTS AND PERFORMANCE
REVIEW OF ACTIVITIES
Melanoma Focus is unique in its field, combining the functions of patient support and advocacy with the role of providing representation and up-to-date information for UK healthcare professionals involved in melanoma. The charity's objectives (see Page 3) have recently been reviewed and amended, better to reflect the full range of these activities.
Melanoma Focus usually organises two professional meetings a year; the Regional meeting in May and the Focus meeting in October. The May meeting (like most face-to face events) was cancelled due to Covid-19. The charity spent time investigating executing a virtual event in October 2020 which was successfully orchestrated with the organiser Professor Marc Moncrieff. The virtual concept proved to be very popular and the scientific feedback was excellent. The charity managed to devise virtual networking and additional content with ‘meet the expert’ sessions. It was important, especially during Covid-19, to provide superb opportunities for clinicians and nurses to network and keep up-to-date with the rapidly-changing progress in melanoma medicine, while allowing clinicians and industry representatives to meet on neutral ground.
Meanwhile the charity's work in funding, convening and supporting development groups to publish clinical guidelines for rarer forms of melanoma continued virtually. Following the previous years' successes in producing ano-uro-genital mucosal melanoma guidelines, and head & neck mucosal melanoma led by Professor Kevin Harrington, completed and published its work. The update of uveal (ocular) guidelines (originally published in 2015) got underway reviewing areas where there has been a change in the evidence. This work is being carried out under the chairmanship of Dr Paul Nathan, in partnership with the charity Ocumel.
All the guidelines developed under Melanoma Focus auspices are based on NICE-accredited methodology and bear the NICE kitemark.
At the end of 2020, Melanoma Focus put out a call to fund, to a maximum individual value of £20,000, research projects for patient benefit. Four projects were supported.
The usage of the Melanoma Helpline increased five-fold during Covid-19 and the charity prioritised the expansion of this service after successfully applying for various Pharma and lottery funding. Two additional experienced skin cancer nurses were funded to support the additional opening hours so that further patients, carers and the general public could be supported.
Melanoma Focus set up the Database project in 2012 . The aim was to collect data on melanoma and other skin cancers, enabling individual NHS centres to plan and audit their services while performing research individually or in collaboration with other participating centres.
Page 3
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2021
OBJECTIVES AND ACTIVITIES (CONTINUED)
Following a series of board meetings to review the datasets and consider the future of the project, the charity came to the following conclusions and decisions:
-
Establishing and supporting large-scale IT projects outside the NHS remit is extremely challenging. Whilst this has worked very well in some centres, others have struggled to recruit people to enter data and have therefore been unable to engage fully with the project. This has meant that the quality of the information collected has been variable. Nonetheless the data captured totals more than 10,000 records of reasonable quality but now needing various degrees of enhancement.
-
As a consequence, Melanoma Focus has decided to stop recruiting further centres into the project apart from the set-up in the agreed centres. The centres currently using the database may continue to do so outside the project,
-
Melanoma Focus has formed a subgroup under Dr Samra Turajlic to assess the data and produce scientific publications.
Financial and legal advice was sought to ensure that the review and processes were reasonable and justifiable and additional restricted funds were transferred to general funds.
ACHIEVEMENTS AND PERFORMANCE (CONT.)
a. REVIEW OF ACTIVITIES
Other projects and activities included: updating the popular Patient Decision Aid, which gives patients an authoritative source of information on all aspects of cutaneous melanoma, equipping them to become more fully involved in decisions affecting their condition is underway. During Covid-19, clinical trials were generally put on hold as the NHS concentrated on the frontline service and therefore the charity deprioritised and delayed its work on the new online facility to help patients and clinicians identify suitable melanoma clinical trials to work on the expansion of the Melanoma Helpline and the virtual professional meeting.
The charity runs on minimal staffing and therefore during Covid, no staff needed to be furloughed, however, there was a regular review and prioritisation of activities.
At the end of year actions were in hand to identify a successor to Simon Rodwell, CEO of Melanoma Focus since its creation in its current form in 2012, who is due to retire during 2020. Susanna Daniels, currently the Deputy CEO, has now been confirmed for this role.
FINANCIAL REVIEW
a. GOING CONCERN
After making appropriate enquiries, including assessing the impact of Covid-19, the Trustees have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the accounting policies.
Page 4
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2021
b. RESERVES POLICY
At the end of the year there were reserves of £256,274 (2020: £237,878) comprising £29,911 of restricted funds and £226,363 of unrestricted funds. The charity’s income is mainly from donations and discretionary sponsorship.
The Trustees aim to maintain free reserves in unrestricted funds at a desired level of £120,000, with a minimum necessary of £100,000. After taking appropriate advice, a transfer was made from the restricted database project to unrestricted funds as detailed in the notes to the accounts. The database project is nearing completion and should close in the next year or so. This has boosted unrestricted funds and free reserves (unrestricted funds excluding amounts tied up in fixed assets) at 31 January 2021 are £226,363 (2020: £44,248) however a call out has been made to researchers in the field of melanoma to put forward proposals for projects. The Trustees intend to offer suitable projects up to £20,000 in funding to assist with their work, which should be completed within 3 years.
The level of reserves is considered to be reasonable and the charity remains in a position to support its current commitments over the next few years, as well as able to embark on our other planned initiatives. A cautious attitude will be maintained, especially over expenditure on indirect costs, and the Trustees will continue to review the level of free reserves periodically.
c. RESULTS FOR THE YEAR
As previously, the wide range of events and initiatives in which Melanoma Focus takes part accounted for a significant proportion of our income. Melanoma Focus received donations and other voluntary contributions totalling £181,645 (2020: £97,156) as well as membership subscriptions and income from the Focus and Regional meetings of £27,212 (2020: £44,445). Corporate sponsorship income was £53,500 (2020: £77,500). Sponsorship and meeting income was adversely affected by the pandemic in 2020.
The charity spent £30,155 (2020: £36,333) on the cost of raising funds. Expenditure on the charity's main projects – the National Melanoma Database project and the Helpline was £66,677 (2020: £65,385). Total expenditure amounted to £244,614 (2020: £285,431) for the year, of which £69,037 (2019: £43,544) was met from restricted funds.
Net income for the year was £18,396 (2020: net expenditure £65,007), which has increased the charity's funds to £256,274 of which £29,911 were restricted and £226,363 were unrestricted.
STRUCTURE, GOVERNANCE AND MANAGEMENT
a. CONSTITUTION
Melanoma Focus is registered as a charitable company limited by guarantee and was set up by a Memorandum of Association on 3 January 2008, with charity registration number 1124716.
It was decided to change the official name of the charity from 'Melanoma Research Foundation Limited' to 'Melanoma Focus' – the name by which it is generally known – in all official and business contexts including registration with Companies House and the Charity Commission. This change was registered at Companies House on 25 August 2020.
Page 5
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2021
STRUCTURE, GOVERNANCE AND MANAGEMENT (CONTINUED)
b. METHODS OF APPOINTMENT OR ELECTION OF TRUSTEES
The company is the responsibility of the trustees who are elected in accordance with the terms in its Memorandum of Association. All directors of the company are also trustees of the charity, and there are no other trustees. The trustees named below served in the year. The board has the power to appoint additional trustees as it considers fit to do so based on their suitability for the role. A board skills audit is planned for 2021 with a view to expand the skillset of the board.
The Trustees who served during the year were:
Dr Katharine Acland (resigned 16 October 2020) Mrs Imogen Cheese Professor Martin Gerald Cook (resigned 30 June 2021) Dr Philippa Gail Corrie Dr Mark Harries Professor Catherine Anne Harwood Mrs Jacqueline Anne Hodgetts Professor Paul Lorigan Dr Jeremy Robert Marsden (resigned 18 March 2021) Dr Paul Nathan Mr Alan Howard Skyrme Peach Professor Barry Willoughby Eric Merrick Powell (resigned 16 October 2020) Dr Samra Turajlic
c. ORGANISATIONAL STRUCTURE AND DECISION-MAKING
The charity's organisational structure consists of a board of Trustees, of which there were nine at the year end. The Board of Trustees meets three to four times a year to review the charity’s operations and strategy. At other times all Trustees are kept informed of issues affecting the charity and they contribute in making key decisions. The extent to which Trustees’ responsibilities for decisions affecting the development and operation of the charity are devolved, day to day, to the CEO is set out in the CEO’s contract of employment and terms of reference.
FUTURE ACTIVITIES
During 2021 our principal activities and projects will include:
-
widening the scope of our online Patient Decision Aid;
-
expanding our national Melanoma Helpline to meet the growing need for support during Covid-19 and beyond;
-
developing TrialFinder, a unique online searchable tool for UK melanoma trials (delayed due to Covid-19);
-
• piloting the Melanoma Forum, a private, online facility for our clinician and nurse members to raise queries and discuss topics;
-
continuing work on updating our clinical guideline for ocular melanoma;
-
upgrading our website;
-
organising our two virtual annual melanoma conferences for clinicians and nurses using the learnings of our initial virtual meeting in October 2020
Page 6
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS (A Company Limited by Guarantee)
TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2021
STATEMENT OF TRUSTEES' RESPONSIBILITIES
The Trustees (who are also the directors of the Company for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).
Company law requires the Trustees to prepare financial statements for each financial . Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:
-
select suitable accounting policies and then apply them consistently;
-
observe the methods and principles of the Charities SORP (FRS 102);
-
make judgments and accounting estimates that are reasonable and prudent;
-
state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
-
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.
The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Approved by order of the members of the board of Trustees and signed on their behalf by:
................................................
Dr Mark Harries
Chairman
Date: 09 September 2021 | 15:00 BST
Page 7
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS (A Company Limited by Guarantee)
INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 JANUARY 2021
Independent Examiner's Report to the Trustees of Melanoma Focus ('the Company')
I report to the charity Trustees on my examination of the accounts of the Company for the year ended 31 January 2021.
Responsibilities and Basis of Report
As the Trustees of the Company (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').
Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Company's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.
Independent Examiner's Statement
Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
-
accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
-
the accounts do not accord with those records; or
-
the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
-
the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
Page 8
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
INDEPENDENT EXAMINER'S REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2021
This report is made solely to the Company's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Company's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Company and the Company's Trustees as a body, for my work or for this report.
Signed:
Dated: 14 September 2021 | 09:21 BST
M Hewett ACA DChA Peters Elworthy & Moore
Chartered Accountants
Cambridge
Page 9
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 JANUARY 2021
| Note Income from: Donations, grants and legacies 2 Charitable activities 3 Other trading activities 4 Investments 5 Total income Expenditure on: Raising funds 6 Charitable activities 7 Total expenditure Net income/(expenditure) Transfers between funds 15 Net movement in funds Reconciliation of funds: Total funds brought forward Net movement in funds Total funds carried forward |
Unrestricted funds 2021 £ 115,325 27,212 53,900 253 196,690 30,155 145,422 175,577 21,113 156,902 178,015 48,348 178,015 226,363 |
Restricted funds 2021 £ 66,320 - - - 66,320 - 69,037 69,037 (2,717) (156,902) (159,619) 189,530 (159,619) 29,911 |
Total funds 2021 £ 181,645 27,212 53,900 253 263,010 30,155 214,459 244,614 18,396 - 18,396 237,878 18,396 256,274 |
Total funds 2020 £ 97,156 44,445 77,999 824 |
|---|---|---|---|---|
| 220,424 36,333 249,098 |
||||
| 285,431 (65,007) - |
||||
| (65,007) 302,885 (65,007) |
||||
| 237,878 |
The Statement of Financial Activities includes all gains and losses recognised in the year.
The notes on pages 13 to 27 form part of these financial statements.
Page 10
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS (A Company Limited by Guarantee) REGISTERED NUMBER: 06057181
BALANCE SHEET AS AT 31 JANUARY 2021
| Note Fixed assets Tangible assets 11 Current assets Debtors 12 Cash at bank and in hand Creditors: amounts falling due within one year 13 Net current assets Total assets less current liabilities Creditors: amounts falling due after more than one year 14 NET ASSETS Total net assets Charity funds Restricted funds 15 Unrestricted funds 15 Total funds |
25,102 352,556 377,658 (126,299) |
2021 £ 4,915 4,915 251,359 256,274 - 256,274 256,274 29,911 226,363 256,274 |
47,498 346,362 393,860 (139,249) |
2020 £ 4,100 |
|---|---|---|---|---|
| 4,100 254,611 |
||||
| 258,711 (20,833) |
||||
| 237,878 | ||||
| 237,878 189,530 48,348 |
||||
| 237,878 |
The Company was entitled to exemption from audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.
The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.
The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.
Page 11
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS (A Company Limited by Guarantee) REGISTERED NUMBER: 06057181
BALANCE SHEET (CONTINUED) AS AT 31 JANUARY 2021
The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:
................................................
Dr Mark Harries
Chairman
Date: 09 September 2021 | 15:00 BST
The notes on pages 13 to 27 form part of these financial statements.
Page 12
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
(A Company Limited by Guarantee)
MELANOMA FOCUS
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2021
1. ACCOUNTING POLICIES
1.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS
The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (second edition of the Charities SORP (FRS102) October 2019, effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.
Melanoma Focus meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.
There were no significant estimates or judgements made by management in preparing these financial statements.
1.2 GOING CONCERN
The Trustees have reviewed the financial position of the charity, including the impact of Covid-19, and have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Accordingly, the financial statements continue to be prepared on the going concern basis.
1.3 FUND ACCOUNTING
General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Company and which have not been designated for other purposes.
Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.
Page 13
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
(A Company Limited by Guarantee)
MELANOMA FOCUS
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2021
1. ACCOUNTING POLICIES (CONTINUED)
1.4 INCOME
All income is recognised once the Company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.
The recognition of income from legacies is dependent on establishing entitlement, the probability of receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of entitlement to a legacy exists when the Company has sufficient evidence that a gift has been left to them (through knowledge of the existence of a valid will and the death of the benefactor) and the executor is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of a legacy must be recognised when it is probable that it will be received and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the Company, can be reliably measured.
Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.
Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.
Income from funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.
Meeting income is recognised in the period to which it relates. Income received in advance is carried forward as deferred income on the balance sheet. Any amounts owing to the charity for meetings which have occurred during the accounting period are included as debtors.
Membership income is recognised in the period in which it is received.
Grant income is recognised in the period to which it relates. Any income received in advance is carried forward as deferred income.
Donations raised through JustGiving and related gift aid are recognised in the period in which the income is transferred to the company's bank account. Other donations raised directly are recognised when receivable and the amount can be measured reliably by the charity.
Sponsorship income is recognised once the charity has received confirmation that the funding will be paid and the sum has been agreed, which may occur when a formal agreement is signed or may arise by a verbal or other written communication.
Page 14
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
(A Company Limited by Guarantee)
MELANOMA FOCUS
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2021
1. ACCOUNTING POLICIES (CONTINUED)
1.5 EXPENDITURE
Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.
Support costs are those incurred directly in support of the charitable activities and the general running of the charity.
Governance costs are those incurred in connection with administration of the charity, and to ensure compliance with constitutional and statutory requirements.
Expenditure on raising funds includes all expenditure incurred by the Company to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.
Expenditure on charitable activities is incurred on directly undertaking the activities which further the Company's objectives, as well as any associated support costs.
Grants payable on projects undertaken are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.
All expenditure is inclusive of irrecoverable VAT.
1.6 TANGIBLE FIXED ASSETS AND DEPRECIATION
Tangible fixed assets costing £250 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.
Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.
Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, on a reducing balance basis.
Depreciation is provided on the following basis:
| Fixtures and fittings | - | 25% reducing balance |
|---|---|---|
| Computer equipment | - | 25% reducing balance |
| Website | - | 25% reducing balance |
1.7 DEBTORS
Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.
Page 15
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2021
1. ACCOUNTING POLICIES (CONTINUED)
1.8 CASH AT BANK AND IN HAND
Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.
1.9 PENSIONS
The Company operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Company to the fund in respect of the year.
1.10 LIABILITIES AND PROVISIONS
Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.
Liabilities are recognised at the amount that the Company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.
Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of Financial Activities as a finance cost.
1.11 FINANCIAL INSTRUMENTS
The Company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.
2. INCOME FROM DONATIONS, GRANTS AND LEGACIES
| Unrestricted funds 2021 £ Donations 110,325 Legacies 5,000 Grants - 115,325 TOTAL 2020 97,156 |
Restricted funds 2021 £ - - 66,320 66,320 - |
Total funds 2021 £ 110,325 5,000 66,320 181,645 97,156 |
Total funds 2020 £ 97,156 - - |
|---|---|---|---|
| 97,156 | |||
Page 16
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2021
3. INCOME FROM CHARITABLE ACTIVITIES
| Unrestricted funds 2021 £ Membership fees 6,312 Focus on Melanoma meeting income 20,936 Regional meeting income (36) 27,212 TOTAL 2020 44,445 |
Total funds 2021 £ 6,312 20,936 (36) 27,212 44,445 |
Total funds 2020 £ 5,417 26,257 12,771 |
|---|---|---|
| 44,445 | ||
Page 17
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS (A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2021
4. INCOME FROM OTHER TRADING ACTIVITIES
Income from fundraising events
| Unrestricted funds 2021 £ Sales of merchandise 400 TOTAL 2020 499 Income from non charitable trading activities Unrestricted funds 2021 £ Corporate sponsorship for Focus on Melanoma meetings 51,500 Corporate sponsorship for Regional meetings 2,000 53,500 TOTAL 2020 77,500 |
Total funds 2021 £ 400 499 Total funds 2021 £ 51,500 2,000 53,500 77,500 |
Total funds 2020 £ 499 |
|---|---|---|
| Total funds 2020 £ 51,500 26,000 |
||
| 77,500 | ||
5. INVESTMENT INCOME
| Unrestricted funds 2021 £ Deposit account interest 253 TOTAL 2020 824 |
Total funds 2021 £ 253 824 |
Total funds 2020 £ 824 |
|---|---|---|
Page 18
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2021
6. EXPENDITURE ON RAISING FUNDS
COSTS OF RAISING VOLUNTARY INCOME
| Unrestricted funds 2021 £ Fundraising Activities 5,350 Fundraising Officer 24,805 30,155 TOTAL 2020 36,333 |
Total funds 2021 £ 5,350 24,805 30,155 36,333 |
Total funds 2020 £ 6,758 29,575 |
|---|---|---|
| 36,333 | ||
7. ANALYSIS OF CHARITABLE EXPENDITURE
| Total costs TOTAL 2020 |
Activities undertaken directly 2021 £ 180,838 223,666 |
Support costs 2021 £ 33,621 25,432 |
Total funds 2021 £ 214,459 249,098 |
Total funds 2020 £ 249,098 |
|---|---|---|---|---|
In 2020 £43,544 of expenditure was met from restricted funds with the balance met from unrestricted funds.
Page 19
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS (A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2021
7. ANALYSIS OF CHARITABLE EXPENDITURE (CONTINUED)
ANALYSIS OF DIRECT COSTS
| Staff costs Depreciation and (profit)/loss on disposal of fixed assets Melanoma database project (note 8) Patient Impact Programme (PIP) project Meeting costs Travel, accommodation and subsistence Ocular project Mucosal project Helpline PDA project Minor projects Trial Finder project Uveal Guideline Review project TOTAL 2020 |
Activities 2021 £ 93,819 1,422 35,128 - 6,832 845 - 4,973 31,549 310 1,410 1,542 3,008 180,838 223,666 |
Total funds 2021 £ 93,819 1,422 35,128 - 6,832 845 - 4,973 31,549 310 1,410 1,542 3,008 180,838 223,666 |
Total funds 2020 £ 69,704 1,284 43,544 1,943 46,547 1,738 263 15,782 21,841 1,020 - 20,000 - |
|---|---|---|---|
| 223,666 | |||
Page 20
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS (A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2021
7. ANALYSIS OF CHARITABLE EXPENDITURE (CONTINUED) ANALYSIS OF SUPPORT COSTS
| Activities 2021 £ Rent 12,561 Bank charges 13 Office consumables - Miscellaneous 1,451 Postage and stationery 175 Advertising and promotion (including digital & social media consultancy fees) 8,552 Computer, website and internet 1,752 Legal and professional fees 5,241 Independent examination and accountancy fees 3,876 33,621 TOTAL 2020 25,432 8. MELANOMA DATABASE PROJECT COSTS ICARSIS database fees for Nottingham Royal Preston fee waived ICARSIS database fees for St George's Hospital ICARSIS database fee waived Payments to cover the post of database administrator at St George's Hospital Payments to cover the post of database administrator at Nottingham Other project expenses Project finalisation payment |
Total funds 2021 £ 12,561 13 - 1,451 175 8,552 1,752 5,241 3,876 33,621 25,432 2021 £ 10,000 (2,500) - - - 25,000 128 2,500 35,128 |
Total funds 2020 £ 12,520 107 77 150 1,423 - 3,527 4,448 3,180 |
|---|---|---|
| 25,432 2020 £ - - 25,000 (7,500) 25,000 - 1,044 - 43,544 |
Page 21
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2021
9. INDEPENDENT EXAMINER'S REMUNERATION
| 2021 | 2020 | |
|---|---|---|
| £ | £ | |
| Fees payable to the Company's independent examiner for the independent | ||
| examination of the Company's annual accounts | 1,200 | 1,140 |
| Fees payable to the Company's independent examiner in respect of: | ||
| All accountancy services not included above | 2,676 | 2,040 |
10. STAFF COSTS
| Wages and salaries Social security costs Contribution to defined contribution pension schemes |
2021 £ 87,953 4,411 1,455 93,819 |
2020 £ 66,229 2,876 599 |
|---|---|---|
| 69,704 |
The average number of persons employed by the Company during the year was as follows:
| 2021 | 2020 | |
|---|---|---|
| No. | No. | |
| Charitable activities | 3 | 3 |
No employee received remuneration amounting to more than £60,000 in either year.
The charity considers its key personnel to be the Trustees and Chief Executive. Mr S H Rodwell retired during the year and was replaced by Ms S Daniels. There was a period of handover and in combination for the year, the Chief Executives were paid a total gross annual salary (including Employer's National Insurance Contributions and Employer's Pension) of £74,354 (2020: £38,872) during the year. The Trustees all give their time and expertise without any kind of remuneration or other benefit in kind (2019: £Nil).
During the year, voluntary contributions and donations totalling £nil were received from trustees (2020: £263 from 3 trustees). One Trustee was reimbursed £19 for travel expenses. No other Trustees received any reimbursement of expenses or had expenses paid directly to a third party on their behalf (2020: £nil).
Page 22
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2021
11. TANGIBLE FIXED ASSETS
| COST OR VALUATION At 1 February 2020 Additions Disposals At 31 January 2021 DEPRECIATION At 1 February 2020 Charge for the year On disposals At 31 January 2021 NET BOOK VALUE At 31 January 2021 At 31 January 2020 |
Fixtures and fittings £ 924 - - 924 723 50 - 773 151 201 |
Computer equipment £ 6,730 2,237 (489) 8,478 3,990 926 (334) 4,582 3,896 2,740 |
Website £ 11,894 - - 11,894 10,735 291 - 11,026 868 1,159 |
Total £ 19,548 2,237 (489) |
|---|---|---|---|---|
| 21,296 | ||||
| 15,448 1,267 (334) |
||||
| 16,381 | ||||
| 4,915 | ||||
| 4,100 |
12. DEBTORS
| DUE WITHIN ONE YEAR Other debtors Prepayments and accrued income |
2021 £ - 25,102 25,102 |
2020 £ 36,530 10,968 47,498 |
|---|---|---|
Page 23
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2021
13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
| Other taxation and social security Other creditors Project commitments Accruals and deferred income DEFERRED INCOME Deferred income at 1 February 2020 Resources deferred during the year (income for Focus/Regional meetings and grant income) Amounts released from previous periods (income for Focus/Regional meetings and grant income) |
2021 £ 979 368 68,292 56,660 126,299 2021 £ 71,500 32,833 (69,000) 35,333 |
2020 £ 1,613 1,423 40,000 96,213 |
|---|---|---|
| 139,249 | ||
| 2020 £ 64,978 46,500 (39,978) |
||
| 71,500 |
14. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
| 2021 | 2020 | |
|---|---|---|
| £ | £ | |
| Deferred income | - | 20,833 |
Grant income of £20,833 was deferred and is now included in deferred income within one year, with this amount to be released in the year ending 31 January 2022.
Page 24
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS (A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2021
15. STATEMENT OF FUNDS
| STATEMENT OF FUNDS | ||||
|---|---|---|---|---|
| STATEMENT OF FUNDS - CURRENT YEAR Balance at 1 February 2020 £ UNRESTRICTED FUNDS Unrestricted Funds 48,348 RESTRICTED FUNDS Restricted - National Melanoma Database 189,530 PDA project - Trial Finder project - Melanoma Helpline - Uveal Guideline Review project - 189,530 TOTAL OF FUNDS 237,878 |
Income £ 196,690 - 20,000 2,000 39,320 5,000 66,320 263,010 |
Expenditure £ (175,577) (32,628) (310) (1,542) (31,549) (3,008) (69,037) (244,614) |
Transfers in/out £ 156,902 (156,902) - - - - (156,902) - |
Balance at 31 January 2021 £ 226,363 |
| UNRESTRICTED FUNDS Unrestricted Funds RESTRICTED FUNDS Restricted - National Melanoma Database PDA project Trial Finder project Melanoma Helpline Uveal Guideline Review project TOTAL OF FUNDS |
||||
| - 19,690 458 7,771 1,992 |
||||
| 29,911 | ||||
| 256,274 |
The National Melanoma Database restricted fund has been set up in order to create a database of melanomas, treatment patterns and success rates. The project is drawing to a close and a transfer has been made of the unspent funds following appropriate advice, to be used on alternative research projects at the discretion of the Trustees. All remaining costs relating to the project that are yet to be paid have been accrued in these accounts.
The Patient Decision Aid (PDA) project has currently received generous funds from MSD and Novartis.
The Trial Finder project received £2,000 from The Hospital Saturday Fund to help fund work on the Melanoma Trials Database.
Funds have been received from Pierre Fabre (£5,000), The Edward Gostling Foundation (£5,000), The Fred and Charlie Allen Charitable Trust (£3,000), Bristol-Myers Squibb Pharmaceuticals Limited (£9,360) and £10,000 from the Coronavirus Community Support Fund (The National Lottery Community Fund) towards the Melanoma Helpline project.
The Uveal Guideline Review project received funding of £5,000 from OcuMel UK to fund the guideline review work.
Page 25
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2021
| 15. STATEMENT OF FUNDS (CONTINUED) STATEMENT OF FUNDS - PRIOR YEAR Balance at 1 February 2019 £ Income £ UNRESTRICTED FUNDS Unrestricted Funds 69,811 220,424 RESTRICTED FUNDS Restricted - National Melanoma Database 233,074 - TOTAL OF FUNDS 302,885 - 16. ANALYSIS OF NET ASSETS BETWEEN FUNDS ANALYSIS OF NET ASSETS BETWEEN FUNDS - CURRENT PERIOD Unrestricted funds 2021 £ Tangible fixed assets 4,915 Current assets 264,124 Creditors due within one year (42,676) TOTAL 226,363 |
Expenditure £ (241,887) (43,544) (285,431) Restricted funds 2021 £ - 113,534 (83,623) 29,911 |
Balance at 31 January 2020 £ 48,348 189,530 237,878 Total funds 2021 £ 4,915 377,658 (126,299) 256,274 |
|---|---|---|
Page 26
DocuSign Envelope ID: EBC3EA5F-E481-471D-A155-0DF16B41BE39DocuSign Envelope ID: 3CC63ECF-C8DB-4432-A0D8-57B9BB279DB6
MELANOMA FOCUS
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2021
16. ANALYSIS OF NET ASSETS BETWEEN FUNDS (CONTINUED)
ANALYSIS OF NET ASSETS BETWEEN FUNDS - PRIOR PERIOD
| Tangible fixed assets Current assets Creditors due within one year Creditors due in more than one year TOTAL |
Unrestricted funds 2020 £ 4,100 161,830 (104,249) (13,333) 48,348 |
Restricted funds 2020 £ - 232,030 (35,000) (7,500) 189,530 |
Total funds 2020 £ 4,100 393,860 (139,249) (20,833) 237,878 |
|---|---|---|---|
17. PENSION COMMITMENTS
The company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge representing employer contributions payable by the company to the fund amounted to £1,455 (2020: £599). Contributions of £288 (2020: £94) were payable to the fund at the balance sheet date.
18. RELATED PARTY TRANSACTIONS
There were no related party transactions during the year other than disclosed in note 10.
Page 27